Hormone Sensitive Prostate Cancer

P2, N=202, Not yet recruiting, Mayo Clinic

P2, N=254, Not yet recruiting, West China Hospital

The patient had undergone laparoscopic radical prostatectomy 5 years prior and received intermittent postoperative endocrine therapy with leuprorelin acetate and bicalutamide...Following a change in the endocrine therapy regimen to rezvilutamide combined with degarelix, the patient's hematuria significantly improved. This case highlights the critical importance of rigorous postoperative surveillance and timely, standardized endocrine therapy in prostate cancer management. It also contributes to the limited literature on visceral metastases in castration-sensitive prostate cancer (HSPC) and underscores the need for further exploration of optimal treatment strategies for advanced metastatic disease.

P2, N=108, Not yet recruiting, Georgetown University

Importantly, the inhibitory effect of 1168 on HSP70 expression was markedly attenuated upon HSF1 knockdown, supporting HSF1-dependent activity in cells. Collectively, these findings identify 1168 as a direct HSF1-DBD-binding inhibitor and establish borylated aza-arenes as a promising chemotype for the development of HSF1-targeted anticancer agents.

P=N/A, N=400, Recruiting, AstraZeneca | Trial completion date: Jun 2028 --> Nov 2028 | Trial primary completion date: Jun 2028 --> Nov 2028

Abiraterone acetate was initiated immediately...Autopsy revealed widespread metastases, all histologically confirmed as neuroendocrine prostate cancer. Strong androgen receptor suppression in metastatic castration-sensitive prostate cancer can lead to aggressive radiographic progression without prostate-specific antigen elevation, underscoring the limitations of antigen-based monitoring.

We retrospectively analyzed 148 patients with mHSPC treated with either ARPI (abiraterone, enzalutamide, or apalutamide) plus androgen deprivation therapy (ADT) (n = 98) or docetaxel plus ADT (n = 50). In this real-world cohort, ARPI-based therapy was associated with an improvement in rPFS compared with docetaxel, while OS outcomes remained comparable. In the absence of direct randomized comparisons, these findings may provide supportive real-world evidence for the clinical relevance of ARPI-based therapy as a first-line treatment option for patients with mHSPC.

P=N/A, N=400, Suspended, AstraZeneca | Recruiting --> Suspended

To antagonize the ACSL4-conferred ferroptosis risk, SCL/NEL cells upregulated GPX4 through AP-1 transcription complex to suppress ferroptosis and thus promoted the malignant progression of SCL/NEL cells. Notably, we characterized Auranofin, an anti-rheumatoid arthritis drug, as a ferroptosis inducer for these SCL/NEL cells in vitro and in vivo by targeting AP-1 and decreasing GPX4 expression, suggesting a new application for Auranofin in treating enzalutamide-resistant stem cell-like AP-1High CRPC.

P3, N=1889, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2028 --> Sep 2027